Cel
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a wealth of clinical data. Furthermore our cohorts include genetic and genome data, allowing us to carefully select subjects for hiPSC based disease model development. This clinical-genetic stratification is essential to ensure that cellular models display disease and therapy relevant phenotypes. hiPSC reprogramming is undertaken by an internationally respected centre, providing robust, reliable and timely delivery of hiPSCs; ensures the biorepository only houses quality assured hiPSC lines; and reduces unwanted variability in assays. We have leading experts in hiPSC differentiation, providing protocols with over 99% efficiency in producing cortical excitatory neurons and cardiomyocytes, which following up-scaling will meet demands of high throughput assays. StemBANCC will deliver a comprehensive ‘omics’ dataset on over 1500 stem cell lines. This includes cells taken at different lineage stages, after therapeutic challenge, monogenic and complex variants, and with matched isogenic controls. The integration of this network/pathway data will define core etiopathological processes, therapeutic generality, reveal on- and off-target effects, allow candidate therapeutic repositioning and decouple tolerance and toxicity pathways. The large-scale integrated datasets then directly guide the disease specific targeted assays, designed to maximize utility in low and high- through compound screening programs. Assay development undertaken by the StemBANCC proposed central test facility thereby provides the final component of our hiPSC platform for drug discovery, development and safety.
Dziedzina nauki
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinetoxicology
Zaproszenie do składania wniosków
IMI-JU-04-2011
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Koordynator
4070 Basel
Szwajcaria
Zobacz na mapie
Uczestnicy (37)
OX1 2JD Oxford
Zobacz na mapie
82256 FURSTENFELDBRUCK
Zobacz na mapie
WC2R 2LS London
Zobacz na mapie
WC1E 6BT London
Zobacz na mapie
72770 Reutlingen
Zobacz na mapie
31000 Toulouse
Zobacz na mapie
Zakończenie uczestnictwa
101 Reykjavik
Zobacz na mapie
EH8 9YL Edinburgh
Zobacz na mapie
3400 Hillerod
Zobacz na mapie
B15 2TT Birmingham
Zobacz na mapie
85764 Neuherberg
Zobacz na mapie
10117 Berlin
Zobacz na mapie
23562 Lubeck
Zobacz na mapie
NE1 7RU Newcastle Upon Tyne
Zobacz na mapie
1015 LAUSANNE
Zobacz na mapie
6020 Innsbruck
Zobacz na mapie
1211 Geneve
Zobacz na mapie
75654 Paris
Zobacz na mapie
CB2 1TN Cambridge
Zobacz na mapie
30625 Hannover
Zobacz na mapie
69978 Tel Aviv
Zobacz na mapie
60203 Compiegne Cedex
Zobacz na mapie
581 83 Linkoping
Zobacz na mapie
65205 Wiesbaden
Zobacz na mapie
55218 Ingelheim
Zobacz na mapie
2340 Beerse
Zobacz na mapie
RG21 4FA Basingstoke
Zobacz na mapie
64293 Darmstadt
Zobacz na mapie
2880 Bagsvaerd
Zobacz na mapie
02200 Espoo
Zobacz na mapie
CT13 9NJ Sandwich
Zobacz na mapie
94250 GENTILLY
Zobacz na mapie
Zakończenie uczestnictwa
W1B 1AL LONDON
Zobacz na mapie
91904 Jerusalem
Zobacz na mapie
151 85 Sodertaelje
Zobacz na mapie
60550 Verneuil En Halatte
Zobacz na mapie
NE1 4EP Newcastle Upon Tyne
Zobacz na mapie